ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,626.02
      0.54%
      US Tech 100
      18,986.40
      0.30%
      Dow Jones
      41,393.78
      0.72%
      Brent Oil
      71.825
      0.00%
      Bitcoin
      60,164.87
      0.26%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NYSE
      6. AbbVie Inc (ABBV)

      7. AbbVie Inc (ABBV) News

      ABBV

      AbbVie (ABBV)

      AbbVie Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NYSE:ABBV
      DateTimeSourceHeadlineSymbolCompany
      09/11/20248:30AMPR Newswire (US)Allergan Aesthetics Launches BOTOX® Cosmetic (onabotulinumtoxinA) for Masseter Muscle Prominence (MMP) in Adults in ChinaNYSE:ABBVAbbVie Inc
      09/10/20243:30PMEdgar (US Regulatory)Form 8-K - Current reportNYSE:ABBVAbbVie Inc
      09/10/20247:00AMPR Newswire (Canada)AbbVie reçoit l'approbation de Santé Canada pour l'emploi de CONSTELLA® (linaclotide) dans le traitement de la constipation fonctionnelle chez les enfants âgés de 6 à 17 ansNYSE:ABBVAbbVie Inc
      09/10/20247:00AMPR Newswire (Canada)Health Canada Approves AbbVie's CONSTELLA® (linaclotide) for the Treatment of Functional Constipation in Pediatric Patients 6 to 17 Years of AgeNYSE:ABBVAbbVie Inc
      09/09/20249:00AMPR Newswire (US)AbbVie Showcases Advancement of Solid Tumor Pipeline at ESMO 2024, with New Data in Tumor Types with High Unmet NeedsNYSE:ABBVAbbVie Inc
      09/06/202410:13AMPR Newswire (US)AbbVie Declares Quarterly DividendNYSE:ABBVAbbVie Inc
      09/04/20248:00AMPR Newswire (Canada)AbbVie's VRAYLAR® (cariprazine) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for the Treatment of SchizophreniaNYSE:ABBVAbbVie Inc
      09/04/20248:00AMPR Newswire (Canada)AbbVie reçoit une recommandation favorable de la part de l'Agence des médicaments du Canada pour le remboursement de VRAYLAR® (cariprazine) dans le traitement de la schizophrénieNYSE:ABBVAbbVie Inc
      08/27/20248:15AMPR Newswire (US)AbbVie Awards Scholarships to 45 U.S. Students Living With Chronic Immune-Mediated DiseasesNYSE:ABBVAbbVie Inc
      08/27/20248:05AMPR Newswire (US)SkinMedica® Revolutionizes Skin Hydration with the Introduction of HA5® Hydra Collagen Replenish + Restore HydratorNYSE:ABBVAbbVie Inc
      08/19/20242:05PMPR Newswire (US)European Commission Grants Second Indication Approval for TEPKINLY® (epcoritamab) for the Treatment of Adults with Relapsed/Refractory Follicular LymphomaNYSE:ABBVAbbVie Inc
      08/15/20249:14AMPR Newswire (Canada)AbbVie annonce les premiers remboursements provinciaux, en Ontario et au Québec, d'EPKINLY(MC) (epcoritamab) administré par voie sous-cutanée pour le traitement du lymphome diffus à grandes cellules B en vertu d'un nouveau processus d'accès rapideNYSE:ABBVAbbVie Inc
      08/15/20249:13AMPR Newswire (Canada)AbbVie Announces Ontario and Quebec are First Provinces to Reimburse Subcutaneous EPKINLY™ (epcoritamab) for the Treatment of Diffuse Large B-Cell Lymphoma Under New Early Access ProcessNYSE:ABBVAbbVie Inc
      08/14/20244:09PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNYSE:ABBVAbbVie Inc
      08/08/20245:40PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:ABBVAbbVie Inc
      08/07/20244:22PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:ABBVAbbVie Inc
      08/07/20243:00PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:ABBVAbbVie Inc
      08/01/20248:23AMPR Newswire (US)AbbVie Completes Acquisition of Cerevel TherapeuticsNYSE:ABBVAbbVie Inc
      07/30/20248:00AMPR Newswire (US)Allergan Aesthetics Celebrates the Second Annual JUVÉDERM® DayNYSE:ABBVAbbVie Inc
      07/30/20246:00AMIH Market NewsToyota Reports Another Global Production Decline, Delta Sues CrowdStrike, Meta Launches AI Studio for Custom ChatbotsNYSE:ABBVAbbVie Inc
      07/28/20248:05AMGlobeNewswire Inc.Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)NYSE:ABBVAbbVie Inc
      07/26/20242:00AMPR Newswire (US)AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative ColitisNYSE:ABBVAbbVie Inc
      07/25/20247:41AMEdgar (US Regulatory)Form 8-K - Current reportNYSE:ABBVAbbVie Inc
      07/25/20247:36AMPR Newswire (US)AbbVie Reports Second-Quarter 2024 Financial ResultsNYSE:ABBVAbbVie Inc
      07/25/20246:21AMIH Market NewsU.S. Index Futures Mixed After Tech Sell-Off, Oil Prices Drop on Weak China Demand and Ceasefire ExpectationsNYSE:ABBVAbbVie Inc
      07/23/20247:02AMPR Newswire (Canada)L'Agence des médicaments du Canada octroie à AbbVie sa toute première recommandation de remboursement à durée limitée pour EPKINLY (MC)NYSE:ABBVAbbVie Inc
      07/23/20247:02AMPR Newswire (Canada)AbbVie's EPKINLY™ Receives First-Ever Time-Limited Reimbursement Recommendation by Canada's Drug AgencyNYSE:ABBVAbbVie Inc
      07/12/20248:30AMPR Newswire (US)AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Giant Cell ArteritisNYSE:ABBVAbbVie Inc
      07/10/20248:00AMPR Newswire (US)AbbVie Announces Appointment of Roopal Thakkar, M.D. as Executive Vice President, Research & Development and Chief Scientific OfficerNYSE:ABBVAbbVie Inc
      07/05/20248:13AMIH Market NewsTesla Listed for China’s Government Vehicles; Macy’s Acquisition Offer Raised, and More NewsNYSE:ABBVAbbVie Inc
       Showing the most relevant articles for your search:NYSE:ABBV